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Intrathecal administration of TRPA1
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Abstract
Background: The activation of TRPA1 channel is implicated in hyper-reflexic micturition similar to overactive
bladder. In this study, we aimed to investigate the effects of blocking TRPA1 via intrathecal administration of
antagonists on the afferent pathways of micturition in rats with cystitis.
Methods: The cystitis was induced by intraperitoneal cyclophosphamide administration. Cystometry was performed
in control and cystitis rats, following the intrathecal injection of the TRPA1 antagonists HC-030031 and A-967079.
Real-time PCR, agarose gel electrophoresis, western blotting and immunohistochemistry were used to investigate
the levels of TRPA1 mRNA or protein in the bladder mucosa and L6-S1 dorsal root ganglia (DRG).
Results: Edema, submucosal hemorrhaging, stiffness and adhesion were noted during removal of the inflamed
bladder. The expression of TRPA1 mRNA and protein was higher in the cystitis group in both the mucosa and DRG,
but the difference was significant in the DRG (P < 0.05). Intrathecal administration of HC-030031 and A-967079
decreased the micturition reflex in the cystitis group. A 50 μg dose of HC-030031 increased the intercontraction
interval (ICI) to 183 % of the no-treatment value (P < 0.05) and decreased the non-voiding contraction (N-VC) to
60 % of control (P < 0.01). Similarly, the treatment with 3 μg A-967079 increased the ICI to 142 % of the control
value (P < 0.05) and decreased the N-VC to 77 % of control (P < 0.05). The effects of both antagonists weakened
approximately 2 h after injection.
Conclusions: The TRPA1 had a pronounced upregulation in DRG but more slight in mucosa in rat cystitis. The
blockade of neuronal activation of TRPA1 by intrathecal administration of antagonists could decrease afferent nerve
activities and attenuated detrusor overactivity induced by inflammation.
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Background
The transient receptor potential (TRP) channel A1 is a
non-selective ion channel that can cause an influx of cat-
ions into the cell when activated. It is localized predom-
inantly in small-diameter primary sensory neurons of
the dorsal root ganglion and trigeminal ganglion [1–3].
The TRPA1 receptor has been shown to play crucial
roles in sensory conducting mechanisms in the neural,
respiratory, digestive and other systems as a possible
mechanosensitive receptor, nociceptor or cold receptor
[4–6]. Based on previous studies, TRPA1 has been de-
scribed as an essential gatekeeper, transducer and ampli-
fier of inflammation and pain [7, 8].
The main syndrome of acute cystitis is urinary fre-
quency, urgency and dysuria in addition to the impair-
ment of patient quality of life. Chemical cystitis is the
key adverse effect observed with cyclophosphamide (CY)
chemotherapy, and it results from the formation of acro-
lein, which is a known agonist of TRPA1 [9, 10]. The
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TRPA1 channel has been suggested to mediate mechan-
ical and nociceptive sensitivity in both physiological and
pathological states of the lower urinary tract [11]. In pre-
vious studies, we found that intravesical injection of
TRPA1 agonists induced hyper-reflexic micturition simi-
lar to overactive bladder [12]. Alterations of the TRPA1
channel are known to contribute to mechanical hyper-
sensitivity in primary sensory nerve endings [13]. It is
still debated whether the TRPA1 located in neurons be-
come sensitized to nociceptive or mechanical responses
in response to visceral inflammation. We hypothesize
that the TRPA1 in primary sensory neurons functions as
a mechanical or nociceptive receptor and its activation
may enhance afferent nerve activities induced by over-
active bladder. Therefore the blockade of the TRPA1
channel may be a potential therapeutic target for bladder
overactivity.
Thus the present research was conducted to establish
the animal model of acute cystitis to assess alterations in
the expression and function of TRPA1. We injected
intrathecally the highly specific TRPA1 antagonists HC-
030031 and A-967079 to evaluate the involvement of
TRPA1 in pathological micturition reflex. Two issues
were addressed: First, most antagonists have been ad-
ministered via intravenous or intragastric routes, while
the use of intrathecal administration has been rarely re-
ported. The local intrathecal administration could re-
duce severe gastrointestinal and cardiovascular adverse
effects, thus facilitating the identification of potential
therapeutic strategies; second, if TRPA1 is involved in
the pathological micturition reflex, novel therapeutic
drugs could be developed to target this protein.
Methods
Animals and ethics statement
Female Sprague–Dawley rats (weight 210 to 245 g) were
used. The production, feeding and nursing of the rats
were performed by Experimental Animal Center of
China Medical University (Certification No.2013002R)
and the study was specifically approved by the Animal
Ethics Committee of China Medical University. All sur-
geries were performed under anesthesia, and all efforts
were made to minimize suffering. The animals were
killed under anesthesia (60 mg/kg sodium pentobarbital)
following the recommendations of the US National In-
stitutes of Health.
These rats were housed in standard polypropylene
cages, with four animals per cage, at a temperature-
controlled, humidity-controlled room and 12–12 light/
dark cycle. Cystitis was induced via an intraperitoneal in-
jection of 300 mg/kg CY (Hengrui, China). Sham-treated
rats received normal saline (Huaren, China). The expres-
sion and function studies were performed 48 h after the
injection of CY. For cystometry, the rats were anesthetized
via a subcutaneous injection of 1.2 g/kg urethane (Sigma,
USA).
Histopathology
The excised bladder was fixed immediately in 4 %
buffered formaldehyde for approximately 24 h, dehy-
drated in a series of alcohol concentrations, cleared
in xylene, embedded in paraffin blocks (Thermo ex-
celsior ES, USA), serially sectioned to a thickness of
5 μm and placed on coated slides. Subsequently, the
tissue sections were stained with hematoxylin and
eosin (H&E) dehydrated in a graded ethanol series,
cleared in xylene, and coverslipped using mounting
medium. The slides were examined by light micros-
copy (Olympus IX71, Japan).
Quantitative Reverse Transcriptase-Polymerase Chain
Reaction and AGE (Agarose Gel Electrophoresis)
The L6-S1 DRG and urinary bladder were harvested (n = 6).
Under a stereoscopic microscope, the bladder mucosa was
separated from the muscular layer. Total RNA was ex-
tracted using an RNeasy mini kit and RNase-free DNase kit
(Qiagen, Germany). The detail steps were described as
before [12]. The 2 % agarose gel (Invitrogen, USA) was re-
solved in 1 ×TBE buffer (Tris, Boric acid, EDTA, pH 7.5).
The PCR products supplemented with loading buffer were
electrophoresed in a horizontal apparatus (Bio-Rad, USA) at
150 V for 30 min. The bands were imaged using InGenius
Imager (Syngene, USA) under UV light.
Detection of TRPA1 expression by western blotting
analysis and localization by immunohistochemistry
The DRG and bladder mucosa were dissolved in RIPA
Lysis Buffer (Beyotime, Shanghai, China) containing pro-
tease inhibitor (n = 4). The protein homogenate was cen-
trifuged at 4 °C and 12,000 rpm for 30 min. The Bio-Rad
DC protein assay (model 680; Bio-Rad) was used to detect
the concentration via a BSA standard. Equal proteins were
separated by 8 % SDS-PAGE and then transferred onto a
PVDF membrane. Primary antibodies were incubated on
the membranes for TRPA1 (Abcam, ab68848) (1:400) and
GAPDH (Santa Cruz) (1:1,000) overnight at 4 °C in TBST
and secondary antibodies were incubated at 37 °C for 2 h.
The proteins were detected in an ECL detection system
(UVP Inc., Cambridge, UK) through enhanced chemilu-
minescence detection reagents. We used EC3 Imaging Sys-
tem (UVP Inc.) to catch up the specific bands, and relative
intensities of all bands were quantified using Image J soft-
ware. The ratio between the optical density of the TRPA1
and GAPDH protein was calculated as relative content and
expressed graphically.
The slides were treated with 3 % hydrogen peroxide to
block endogenous peroxidase and with Protein Block
Serum-Free to block nonspecific protein binding. The
Chen et al. BMC Urology  (2016) 16:33 Page 2 of 9
TRPA1 antibody (Abcam, ab68848) was used as a primary
antibody at a dilution of 1:300 for 16 h at 4 °C. After wash-
ing, the slides were incubated with the horseradish perox-
idase (HRP) conjugated secondary antibody (Maixin,
Fuzhou, China) for 30 min at room temperature. Then,
DAB was applied for color development. With the use of
the Image-Pro plus freeware, the intensity of staining was
quantitatively determined in selected areas on digital
image of each slice by normalizing with background value.
Cystometry
Prior to the study, all of the rats had free access to food
and water. The rats were fixed to the plate in the prone
position. We separated the muscle around the fourth lum-
bar (L4) spinous process, removed the spinous process
and adjacent vertebra, exposed the clearance between L3
and L4 and punctured the yellow ligament gently with a
microneedle. Next, a PE-10 catheter’s tip was handled by
fire in order to avoid neuronal damage; we inserted the
catheter parallel to the longitudinal axis through the cre-
vasse and fixed it on the neck of the animal. The rats were
carefully turned to the supine position, and another PE-50
catheter was inserted into the bladder through the dome.
This catheter was connected through a three-way stop-
cock to a microinjection pump (Beyond, China) and pres-
sure transducer (RM6240, Chengyi, China) as previously
described [12]. We examined the effects of the TRPA1 an-
tagonists via an intrathecal injection of 50 μg HC-030031
and 3 μg A-967079 in normal and cystitis rats [14]. The
intravesical pressure was amplified (RM6240, Chengyi)
and recorded using a computer (ThinkPad, China). Nor-
mal saline (37 °C, pH 7.0 to 7.2) was infused continuously
into the bladder at 45 μl/min. The following parameters
were calculated as the average of five or six stable succes-
sive micturition cycles from the normal (n = 4) and cystitis
groups (n = 4): baseline pressure (BT), pressure threshold
(PT), compliance, intercontraction interval (ICI), mictur-
ition pressure (MP), and non-voiding contraction (N-VC).
N-VC were defined as a rhythmic intravesical pressure in-
crease greater than 5 mmHg from baseline pressure with-
out release of saline from the urethra [12].
Chemicals
The TRPA1 antagonists HC-030031 and A-967079 were
obtained from Sigma-Aldrich. Both antagonists were dis-
solved in 10 % dimethylsulfoxide (DMSO), 5 % Tween
80 and 85 % sterile saline solution. The durgs or vehicle
(sterile saline solution) were injected by intrathecal route
contained 0.5 % DMSO. The administration of vehicle
did not display any effect.
Statistical analysis
All of the data were presented as the mean ± standard
error (SD). The statistical analysis was performed using
Student’s t-test and one-way analysis of variance, with a
significance threshold of P < 0.05.
Results
Histological analysis
The model of cystitis was induced with CY, which has
been used worldwide [15]. Histopathology was con-
ducted 48 h after intraperitoneal injection of saline and
CY (Fig. 1). Macroscopically, the inflamed bladder had a
much thicker wall and weighed more compared with the
normal bladder. Edema, congestion, stiffness and adhe-
sion were noted during removal of the inflamed bladder.
In CY-treated group, a thin epithelium, intense edema
(Fig. 1a), congestion (Fig. 1b), submucosal hemorrhaging
(Fig. 1b), abrasion (Fig. 1c) were markedly increased in
large areas. Moreover, the infiltration of large numbers
of mononuclear inflammatory cells in the edematous
mucosa suggested that CY induced cystitis (Fig. 1d).
However, in the control group, microscopic examination
of the bladder revealed the gross and histopathological
features of the mucosa, urothelium, submucosa and de-
trusor smooth muscle (Fig. 1e-h).
Quantification of TRPA1 mRNA level
The levels of TRPA1 mRNA were quantified using the
housekeeping gene GAPDH as an internal stan-
dard(TRPA1/GAPDH). The values for the normal and
cystitis groups were 0.027 ± 0.01 and 0.051 ± 0.02 in the
DRG (Fig. 2a) and 0.007 ± 0.003 and 0.008 ± 0.004 in the
mucosa (Fig. 2b), respectively. The expression of TRPA1
mRNA was higher in the cystitis group in both the mu-
cosa and DRG, but the difference was significant in the
DRG (P = 0.014). Its expression level for DRG/mucosa
was 3 ~ 6:1, demonstrating the more abundant expres-
sion in the DRG. We also observed that the TRPA1 had
much more expression in the cystitis mucosa than the
normal via AGE and the fat tissue did not express
TRPA1 mRNA, although they expressed GAPDH mRNA
(Fig. 2c).
Quantification of TRPA1 Protein level
Immunohistochemistry and western blotting analysis
of TRPA1 expression in DRG and mucosa of cystitis
and normal group. Representative images of the
TRPA1 expression in DRG (Fig. 3a) and mucosa
(Fig. 3b) with normal group. DRG (Fig. 3c) and mu-
cosa (Fig. 3d) of the cystitis were also be showed.
The immunohistochemistry analysis showed that
TRPA1 in DRG was markedly upregulated in the cyst-
itis group (0.224 ± 0.04 vs 0.151 ± 0.02; Fig. 3g; P =
0.018) while the TRPA1 protein level in cystitis mu-
cosa did not have any significant alteration (0.145 ±
0.02 vs 0.127 ± 0.02; P = 0.4). Accordingly, the western
blotting analysis also showed the TRPA1 protein
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significantly increased in the DRG with cystitis(1.21 ±
0.12 vs 0.98 ± 0.08; Fig. 3h ,i; P = 0.018). Similarly to
the data observed in the TRPA1 mRNA levels, there
was no significant alteration in the protein expression
in mucosa(1.05 ± 0.07 vs 0.86 ± 0.04; P = 0.14).
Cystometry of rats with cystitis
In the cystometrograms, the ICI of the cystitis group de-
creased significantly in comparison with the normal
group (2.55 ± 0.64 vs 4.16 ± 1.02 min; Fig. 4a; P < 0.01).
A decrease in bladder compliance with cystitis was ob-
served significantly (80.83 ± 21.42 vs 128.8 ± 42.07 μl/
mmHg; Fig. 4b; P = 0.03). N-VC increased significantly
in the cystitis group compared with the normal group
(3.83 ± 0.75 vs 0.833 ± 0.40; Fig. 4c; P < 0.01), while the
other parameters such as the baseline pressure, pressure
threshold and micturition pressure were not significantly
different.
Fig. 1 Characteristic histological findings in a cross-section of the bladder wall. “a to d” show the inflamed bladder mucosa consisting of the
urothelium (U), submucosa (SM) and detrusor smooth muscle (DSM). Compared with the controls (e to h), severe submucosal edema (hollow
box), hemorrhagia (black arrow), ulceration (yellow arrow), congestion and inflammatory cell infiltrates (red arrow) were observed in CY-treated
rats (a to d). H&E, reduced from 40×, 100×, 200× to 400×
Fig. 2 The mRNA expression levels of TRPA1 in DRG and bladder mucosa were determined. The TRPA1 mRNA level in DRG (a) and mucosa (b)
during cystitis (filled column, n = 6) was 1.89 times and 1.19 times greater than that in the control group (open column, n = 6), respectively. The
PCR products of the DRG and mucosa (Mu) showed bands of TRPA1 at 358 bp in electrophoresis (c). M: marker; Mu1: normal bladder mucosa;
Mu2: inflammatory bladder mucosa; D1: normal dorsal root ganglion; D2: inflammatory dorsal root ganglion; NC: no reverse-transcriptase
negative control
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Cystometry of the administered antagonists
Figures 5 and 6 showed the changes of cystometry pa-
rameters in cystitis and control group by intrathecal ad-
ministration of 50 μg HC-030031 and 3 μg A-967079,
respectively. In the cystitis group (Fig. 5a ,c), a dose of
50 μg HC-030031 increased the ICI to 183 % of the con-
trol value (P = 0.02). The reduced effectiveness of the
drug resulted in a recovery of the ICI to 140 % of its
control value after 2 h (P = 0.09). The N-VC decreased
to 60 % of the control value (P < 0.01) after HC-030031
infusion and then increased to 62 % approximately 2 h
later (P < 0.01). The baseline pressure, pressure threshold,
micturition pressure and compliance displayed no signifi-
cant difference before and after intrathecal injection of the
drug. The effects of HC-030031 were apparent approxi-
mately 30 min after the intrathecal injection, but the re-
covery was observed after 2 h.
The intrathecal injection of 3 μg A-967079 in the cyst-
itis (Fig. 6a, c) increased the ICI to 142 % of the control
value (P = 0.02). After approximately 2 h, the ICI recov-
ered to 126 % of the control value due to the decreased
drug strength (P = 0.38). N-VC decreased to 77 % of the
control (P < 0.01) after the infusion of A-967079 and in-
creased to 66 % approximately 2 h later. However, a dose
Fig. 3 Immunohistochemistry and western blotting analysis of TRPA1 expression in DRG and mucosa. Representative images of TRPA1
immunostaining in DRG (a) and mucosa (b) of normal groups and cystitis (c and d, respectively). Negative control of DRG (e) and mucosa (f).
Immunohistochemistry (g) and western blotting (h, i) analysis of TRPA1 expression in DRG and mucosa. Each column represents the mean and
vertical lines indicate the SD of 4 animals.*P < 0.05
Fig. 4 Comparison of experimental results between the cystitis and normal group. The cystitis and normal groups were injected with CY and saline,
respectively, and cystometry was performed after 48 h. The values of intercontraction interval (a), compliance (b) and non-voidingcontraction (c) were
obtained from the cystitis group and the normal group, respectively; Each column represents the mean and vertical lines indicate the SD of 6 animals.
*P < 0.05, ** P < 0.01
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of 50 μg HC-030031 (Fig. 5b, d) and 3 μg A-967079
(Fig. 6b, d) had no obvious effects on the cystometry pa-
rameters in the normal group. The effects of antagonists
on micturition were presented in Tables 1 and 2.
Discussion
The present study demonstrates the TRPA1 was expressed
in both bladder and DRG (L6-S1) and had a pronounced
upregulation in DRG but more slight in mucosa in rat
cystitis. The blockade of TRPA1 via intrathecal adminis-
tration decreased afferent nerve activities and conse-
quently attenuated detrusor overactivity markly. More
recently, Tomonori et al. have shown that TRPA1 channel
could improve afferent nerve activities of the rat bladder
through both Aδ- and C-fibers pathway [16]. TRPA1
channels have been conducted in multiple-sensation mo-
dalities at present including mechanical, nociceptive, and
thermal sensation in mammal [17–19].
However, the function of TRPA1 as nociceptor in the
DRG innervating bladder is really quite controversial
and further research is needed. We suppose the activa-
tion of TRPA1 receptors in DRG may lead to hyperalge-
sia, playing a role in enhanced impulse conduction and
detrusor overactivity. We observed hematuria, severe
submucosal edema, hemorrhage, ulceration, congestion
and inflammatory cell infiltration following the intraperi-
toneal injection of CY for 48 h. The symptoms of over-
active bladder, a shortened ICI and an increase in
unstable contractions, were observed concomitantly. In
the present study, the levels of TRPA1 mRNA and pro-
tein in DRG were significantly higher in cystitis group
than the control group while the TRPA1 in mucosa were
slightly higher than the control group without statistical
significance, indicating that the TRPA1 in DRG may play
a greater role than in mucosa. Similarly, Andrade also
found a higher expression of TRPA1 mRNA in DRG
neurons in the study investigating bladder overactivity
induced by spinal cord injury [20]. It also be demon-
strated that the TRPA1 expression level was significantly
higher than bladder mucosa [12]. The possible reason
may refer to the TRPA1 in mucosa might not function
as nociceptive receptor in the case of cyclophosphamide-
induced inflammation. The profound results showed that
the modulation of intracellular Ca2+ could contribute dir-
ectly to the elevated gene expression of TRPA1 via an in-
flux through voltage-gated channels and/or endoplasmic
reticulum [21, 22]. It has also been found that TRPA1 me-
diates inflammation, hyperalgesia and visceral hypersensi-
tivity in pancreatitis pain as well as in a model of acute
gout [23, 24]. The mechanism could be construed as the
Fig. 5 Effects of intrathecal injection of TRPA1 antagonist HC-030031. Representative cystometrograms of intrathecal injection in cystitis (a) and control
(b), respectively. Recovery represents 2 h after intrathecal injection of 50 μg HC-030031. The relative value of 50 μg HC-030031(open column) and the
recovery (filled column) compared with no-treatment in cystitis (c) and control (d) on cystometry parameters, respectively. Each column represents the
mean and vertical lines indicate the SD of 4 animals. ICI: intercontraction interval, N-VC: non-voiding contraction, PT: pressure threshold, MP: micturition
pressure. *P < 0.05, ** P < 0.01
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TRPA1 in DRG played a crucial role in sensitization of
sensory afferent nerves in occurrence of pathological
conditions.
Symptoms of overactive bladder such as a shortened
ICI and an increase in N-VC were observed in cystitis.
We conceive that blocking the TRPA1 in DRG might at-
tenuate the excitability of afferent pathways and thus al-
leviate detrusor overactivity. Following intrathecal
injection of the highly specific TRPA1 antagonists HC-
030031 and A-967079,the ICI was extended, and the N-
VC was suppressed in cystitis, thereby inhibiting mictur-
ition reflex hyperactivity. However, there were no signifi-
cant changes in BP, PT, MP and compliance in CY-
induced rats before and after the application of each
TRPA1 antagonists although the ICI was significantly in-
creased and the number of N-VC was significantly de-
creased. The probable reason is that the cystometry was
performed under anesthetized conditions. Interestingly,
neither HC-030031 nor A-967079 had a substantial ef-
fect on normal urination, suggesting that TRPA1 might
not participate in the physiological micturition reflex.
More TRPA1 channels might need to be open under
pathological conditions, leading to hyperalgesia in the
absence of a physiological pain signal. A study by Perin-
Martins A demonstrated the mechanisms that contrib-
ute to edema and hyperalgesia induced by TRPA1
Fig. 6 Effects of intrathecal injection of TRPA1 antagonist A967079. Representative cystometrograms of intrathecal injection in cystitis (a) and
control (b), respectively. Recovery represents 2 h after intrathecal injection of 3 μg A967079. The relative value of 3 μg A967079 (open column)
and the recovery (filled column) compared with no-treatment in cystitis (c) and control (d) on cystometry parameters, respectively. Each column
represents the mean and vertical lines indicate the SD of 4 animals. ICI: intercontraction interval, N-VC: non-voiding contraction, PT: pressure
threshold, MP: micturition pressure. *P < 0.05, ** P < 0.01




(number)BP (mmHg) PT (mmHg) MP (mmHg) ICI (min)
No-treatment 13.11 ± 6.14 15.86 ± 6.25 24.33 ± 8.78 3.92 ± 1.41 139.10 ± 49.47 0.25 ± 0.5
Control Treatment 11.24 ± 3.11 14.25 ± 3.44 21.54 ± 5.34 4.08 ± 1.32 159.15 ± 76.02 0
Recovery 11.17 ± 3.08 14.86 ± 3.48 21.53 ± 5.14 3.90 ± 0.74 146.46 ± 65.47 0
No-treatment 10.10 ± 5.74 11.83 ± 6.16 19.11 ± 8.01 2.28 ± 0.51 124.78 ± 49.52 3.25 ± 0.5
Cystitis Treatment 7.70 ± 3.29 9.83 ± 3.05 17.29 ± 6.87 4.14 ± 1.05* 98.12 ± 25.15 1.25 ± 0.50**
Recovery 7.39 ± 3.75 10.05 ± 4.25 15.72 ± 7.00 3.10 ± 0.31 136.80 ± 42.92 1.25 ± 0.50**
Results were expressed as mean ± standard error. The “*” or “**” represented the difference was significant between the treatment or recovery and no-treatment
in cystometry parameters. *P < 0.05, ** P < 0.01
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activation [25]. The antagonists prevent and reverse
cystitis, suggesting that TRPA1 is pivotal for the main-
tenance and development of the inflammatory response
and hyperalgesia. The effects of both antagonists persist
for approximately two hours, which is consistent with
previous findings [26]. When the effects of the antago-
nists disappeared, ICI returned, indicating that continu-
ous activation of the TRPA1 in DRG neurons is crucial
to maintain the nociceptor sensitization elicited by in-
flammatory stimulation. This proposal is further sup-
ported by previous findings showing that TRPA1 mediates
sustained hyperalgesic responses in different models [14,
27]. Indeed, it has been demonstrated that spinal blockage
of the N-type and P/Q-type VGCC (voltage-gated calcium
channel) could attenuate inflammatory and nociceptive
events associated with cystitis [10]. Consistent to this no-
tion, TRPA1 located on DRG contributes to the transmis-
sion of nociceptive information to second-order neurons
in the spinal dorsal horn [14, 26].
Studies have showed that HC-030031 and A-967079
were potentially capable of blocking the effect of TRPA1
with a much higher selectivity than other ion channels
[28, 29]. Intrathecal administration of antagonists is
rarely reported compared with antisense oligonucleo-
tides when blocking the TRPA1 in rats. We use intra-
thecal injection, which not only can act directly on DRG
but can reduce the side effects associated. However,
intrathecal administration is a kind of invasive operation
which may also accompany related complications such
as infection, so its clinical application might be limited.
Nevertheless, the intrathecal administration is also a
suitable alternative when faced with refractory bladder
diseases. Taken together, our results indicate that TRPA1
especially in DRG plays a key role in the occurrence of
cystitis, and therefor intrathecal injection of TRPA1 an-
tagonists might be effective in treating detrusor over-
activity. It should be noted that this study has examined
only the TRPA1 expression and function in the stage of
acute inflammation, while a time-dependent change of
TRPA1 after cystitis was not involved. Our data also
showed the duration of the drug lasted only two hours,
and therefore, further research is needed for possibly
clinical applications in future.
Conclusions
The present findings suggested that TRPA1 might only
be involved in pathological rather than physiological
micturition reflex. The blockade of neuronal activation
of TRPA1 via intrathecal administration could decrease
afferent nerve activities and attenuate detrusor over-
activity induced by inflammation. Therefore, in multi-
step sensory pathway, TRPA1 in DRG might be used as
a more effective therapeutic target for the treatment of
pathological micturition.
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(number)BP (mmHg) PT (mmHg) MP (mmHg) ICI (min)
No-treatment 11.83 ± 2.96 12.74 ± 3.4 21.76 ± 1.63 4.80 ± 1.79 91.44 ± 18.19 0.25 ± 0.5
Control Treatment 11.66 ± 3.32 12.42 ± 3.83 20.82 ± 2.84 4.76 ± 1.96 92.88 ± 43.76 0
Recovery 11.71 ± 3.19 12.73 ± 3.83 21.19 ± 2.22 4.68 ± 1.68 104.56 ± 40.19 0
No-treatment 10.54 ± 3.23 11.94 ± 2.88 22.68 ± 4.89 3.64 ± 0.78 80.07 ± 27.31 3.00 ± 0.82
Cystitis Treatment 10.25 ± 3.99 12.00 ± 4.67 22.68 ± 5.28 5.87 ± 0.93* 67.40 ± 7.66 0.75 ± 0.50**
Recovery 9.85 ± 4.37 11.46 ± 4.75 21.96 ± 5.75 4.50 ± 1.59 90.86 ± 34.91 1.25 ± 0.50*
Results were expressed as mean ± standard error. The “*” or “**” represented the difference was significant between the treatment or recovery and no-treatment
in cystometry parameters. *P < 0.05, ** P < 0.01
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